On 1 June 2026, Kintor Pharmaceutical Limited (Kintor Pharma) submitted its Monthly Return for Equity Issuer to the Hong Kong Stock Exchange, covering the period ended 31 May 2026. The filing indicates stable capital structure and continued compliance with public-float requirements.

Authorised share capital remained at 700.00 million ordinary shares with a par value of USD 0.0001 each, equivalent to authorised capital of USD 70,000. No increase or decrease occurred during the month.

Issued share capital was unchanged at 498.66 million ordinary shares. The company held no treasury shares, leaving total issued shares at the same 498.66 million figure recorded at end-April 2026.

Kintor Pharma confirmed that the public float met the Main Board’s initial prescribed threshold of 25 percent as at 31 May 2026.

The filing shows no share options, warrants, convertible securities or other equity arrangements outstanding or exercised during the month, and no other movements in issued or treasury shares.

Chairman and Chief Executive Officer Youzhi Tong signed the return, affirming that all regulatory and listing-rule obligations were satisfied.